COVID-19 vaccines: modes of immune activation and future challenges.

Teijaro, John R; Farber, Donna L

Teijaro, John R; Farber, Donna L.

Teijaro JR; Department of Immunology and Microbiology, Scripps Research institute, La Jolla, CA, USA. teijaro@scripps.edu.
Farber DL; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA. df2396@cumc.columbia.edu.

Nat Rev Immunol ; 21(4): 195-197, 2021 04.

Article in English | MEDLINE | ID: covidwho-1118810

Subject(s)

Adaptive Immunity/immunology; COVID-19 Vaccines/immunology; COVID-19/prevention & control; Immunity, Innate/immunology; 2019-nCoV Vaccine mRNA-1273; Antibodies, Neutralizing/immunology; B-Lymphocytes/immunology; BNT162 Vaccine; COVID-19 Vaccines/therapeutic use; ChAdOx1 nCoV-19; Cytokines/immunology; Dendritic Cells/immunology; Humans; Immunologic Memory/immunology; Interferon Type I/immunology; Plasma Cells/immunology; SARS-CoV-2; T-Lymphocytes/immunology; T-Lymphocytes, Helper-Inducer

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Adaptive Immunity / COVID-19 Vaccines / COVID-19 / Immunity, Innate Topics: Vaccines Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: S41577-021-00526-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google